News | EP Lab | September 27, 2016

European Heart Rhythm Association Releases EHRA White Book 2016 EP Europace Supplement

Annual supplement provides in-depth analysis on increasing atrial fibrillation ablations and CRT use; highlights continued inequalities in ICD therapy across Europe

European Heart Rhythm Association, EHRA White Book 2016, EP Europace supplement, cardiac rhythm device use, Europe

September 27, 2016 — In August, the European Heart Rhythm Association (EHRA) and EP Europace journal announced the release of the supplement to its ninth annual EHRA White Book, developed in partnership with Biotronik. The supplement was released just ahead of the 2016 European Society of Cardiology (ESC) Congress, Aug. 27-31 in Rome.

The 2016 EP Europace Supplement provides deeper analysis into data presented in the ninth annual EHRA White Book, which collects and distributes information on the yearly number of cardiac rhythm device implantations and catheter ablations in 50 of the 56 ESC member countries. Consistent with the findings of previous editions, the EHRA White Book 2016 found persistent inequalities across ESC countries in access to treatment for cardiac arrhythmias. It found many ESC countries, particularly in eastern Europe and those not on the European continent, fall behind western European countries in the use of implantable cardioverter defibrillators (ICDs) in a number of key arrhythmia treatments.

“Having this data helps us assess how well we’re able to treat groups of patients who may have been underserved in the past,” said 2016 EHRA White Book Coordinator Pekka Raatikainen, M.D., Finland. “We still need to address the disparities between countries in terms of access to all arrhythmia treatments, whether the issues have to do with finances, facilities, manpower or training. One of EHRA’s key goals is to reduce this gap in a number of ways, particularly through training and fellowships.”

The EHRA White Book 2016 also found an increase in the number of ablations for atrial fibrillation and ventricular tachycardia, as well as an increase in cardiac resynchronization therapy (CRT) and the use of insertable cardiac monitors (ICMs), among other findings. “It is particularly encouraging to see evidence that the number of ablations for atrial fibrillation continues to increase,” commented 2016 EHRA White Book Co-coordinator David O. Arnar, M.D., Iceland. “In combination with increasing ICM use, also documented in the EHRA White Book, we can not only treat patients, but monitor them continuously post-ablation to better gauge success rates.”

Biotronik has supported the EHRA White Book through an unrestricted educational grant since the first edition in 2008.

For more information: www.escardio.org

Related Content

Stereotaxis Receives Regulatory Approval of e-Contact Module in Canada
Technology | Ablation Systems| December 08, 2017
December 7, 2017 — Stereotaxis Inc.
CardioFocus Announces European CE Mark Approval of HeartLight Excalibur Balloon
Technology | Ablation Systems| October 10, 2017
October 10, 2017 — CardioFocus Inc. recently announced the European CE Mark approval of the HeartLight Excalibur Ball
The Apama Radiofrequency (RF) Balloon Catheter System.
News | Ablation Systems| October 02, 2017
October 2, 2017 — Boston Scientific announced a definitive agreement to acquire Apama Medical Inc., a privately-held
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Medtronic Announces First Enrollments in STOP AF First Clinical Trial
News | Ablation Systems| July 24, 2017
Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the...
Biosense Webster multi-electrode RF ablation balloon

Biosense Webster's multi-electrode RF ablation balloon with irrigation. The system allows operators to change the energy levels of each electrode to avoid damaging sensitive underlying critical structures like the esophagus or phrenic nerve.

Feature | Ablation Systems| May 17, 2017 | Dave Fornell
May 17, 2017 – Clinical trial results from a first-in-human study evaluating the acute feasibility of an investigatio
Abbott Announces CE Mark for New Cardiac Ablation Catheter
News | Ablation Systems| May 10, 2017
Abbott announced CE Mark of the TactiCath Contact Force Ablation Catheter, Sensor Enabled, developed to make it easier...
Medtronic, expanded indication, Freezor Xtra Cryoablation Catheter, AVNRT, atrioventricular nodal re-entrant tachycardia
Technology | Ablation Systems| February 16, 2017
Medtronic plc announced the U.S. Food and Drug Administration (FDA) has approved its Freezor Xtra Cryoablation Catheter...
CardioFocus, HeartLight Excalibur Balloon, 22nd Annual AF Symposium, atrial fibrillation, initial clinical evaluation
News | Ablation Systems| January 25, 2017
CardioFocus Inc. recently announced the initial clinical evaluation of the HeartLight Excalibur Balloon, a next-...
catheter ablations, atrial fibrillation, stroke risk, Intermountain Medical Center Heart Institute study, AHA Scientific Sessions, American Heart Association
News | Ablation Systems| November 14, 2016
Atrial fibrillation patients with a prior history of stroke who undergo catheter ablation lower their long-term risk of...
Overlay Init